Abstract：Objective To analyse the effect of Zoledronic Acid combined with Simvastatin in the treatment of patients with type 2 diabetes(T2DM)and osteoporosis.Methods A total of 64 patients with T2DM and osteoporosis admitted to the Second People′s Hospital of Zhaoqing from October 2018 to July 2019 were selected as the research subjects.They were divided into the combination group(32 cases)and the single-drug group(32 cases)according to the odd and even number grouping method.The single-drug group was treated with Zoledronic Acid,and the combination group was treated with Simvastatin on the basis of the single-drug group.The clinical bone pain symptoms,bone biochemical indicators,density of different parts of the bone,and adverse reactions between the two groups were compared.Results The clinical bone pain symptoms of the combination group were milder than those of the single-drug group,and the differences were statistically significant(P<0.05).There were no significant differences in serum osteocalcin(BGP),bonespecific alkaline phosphatase(BALP),osteoprotegerin(OPG)and blood phosphorus(P)between the two groups before treatment(P>0.05).After 8 months of treatment,the levels of BGP and BALP of the two groups were lower than those before treatment,and those indicators in the combination group were lower than those of the single-drug group; the levels of OPG and phosphorus were both higher than those before treatment,and the two indicators in the combination group were higher compared with those in the single-drug group,and the differences were statistically significant(P<0.05).There were no significant differences in the bone mineral density of the lumbar spine,femoral neck and Ward triangle between the two groups before treatment(P>0.05); after 8 months of treatment,the bone mineral density of the lumbar spine,femoral neck and Ward triangle of the two groups were all higher than those before treatment,and the combination group was higher than that in the group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions after treatment in the combined group was lower than that in the single-drug group,and the difference was statistically significant(P<0.05).Conclusion The combination of Simvastatin and Zoledronic Acid in the treatment of patients with T2DM and osteoporosis can improve their bone biochemical indicators,increase bone density,and reduce bone pain symptoms and adverse drug reactions.
伍博 ;谢明. 唑来膦酸联合辛伐他汀治疗2型糖尿病合并骨质疏松患者的效果分析[J]. 中国当代医药, 2021, 28(22): 151-154.
WU Bo; XIE Ming. Analysis of the effect of Zoledronic Acid combined with Simvastatin in the treatment of patients with type 2 diabetes and osteoporosis. 中国当代医药, 2021, 28(22): 151-154.
京公网安备 11010502046607号